How to buy Entasis Therapeutics stock - 21 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Entasis Therapeutics stock

Own Entasis Therapeutics stock in just a few minutes.

Entasis Therapeutics Holdings Inc is a biotechnology business based in the US. Entasis Therapeutics shares (ETTX) are listed on the NASDAQ and all prices are listed in US Dollars. Entasis Therapeutics employs 47 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Entasis Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ETTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Entasis Therapeutics share price

Use our graph to track the performance of ETTX stocks over time.

Entasis Therapeutics shares at a glance

Information last updated 2021-04-16.
52-week range$1.58 - $4.25
50-day moving average $2.42
200-day moving average $2.37
Wall St. target price$6.29
PE ratio 0.0537
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.33

Buy Entasis Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Entasis Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Entasis Therapeutics under- or over-valued?

Valuing Entasis Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Entasis Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Entasis Therapeutics's P/E ratio

Entasis Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Entasis Therapeutics shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Entasis Therapeutics financials

Gross profit TTM $7 million
Return on assets TTM -60.21%
Return on equity TTM -106.93%
Profit margin 0%
Book value $1.43
Market capitalisation $70.9 million

TTM: trailing 12 months

Shorting Entasis Therapeutics shares

There are currently 226,005 Entasis Therapeutics shares held short by investors – that's known as Entasis Therapeutics's "short interest". This figure is 17.8% down from 274,780 last month.

There are a few different ways that this level of interest in shorting Entasis Therapeutics shares can be evaluated.

Entasis Therapeutics's "short interest ratio" (SIR)

Entasis Therapeutics's "short interest ratio" (SIR) is the quantity of Entasis Therapeutics shares currently shorted divided by the average quantity of Entasis Therapeutics shares traded daily (recently around 265888.23529412). Entasis Therapeutics's SIR currently stands at 0.85. In other words for every 100,000 Entasis Therapeutics shares traded daily on the market, roughly 850 shares are currently held short.

However Entasis Therapeutics's short interest can also be evaluated against the total number of Entasis Therapeutics shares, or, against the total number of tradable Entasis Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Entasis Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Entasis Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0076% of the tradable shares (for every 100,000 tradable Entasis Therapeutics shares, roughly 8 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Entasis Therapeutics.

Find out more about how you can short Entasis Therapeutics stock.

Entasis Therapeutics share dividends

We're not expecting Entasis Therapeutics to pay a dividend over the next 12 months.

Entasis Therapeutics share price volatility

Over the last 12 months, Entasis Therapeutics's shares have ranged in value from as little as $1.58 up to $4.25. A popular way to gauge a stock's volatility is its "beta".

ETTX.US volatility(beta: 1.92)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Entasis Therapeutics's is 1.9199. This would suggest that Entasis Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Entasis Therapeutics overview

Entasis Therapeutics Holdings Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co. , Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate containing zoliflodacin.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site